Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 8/20 | 0.55 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21328343 | 0.91 | PDE4D (0.53) | PDE4DMTNR1BCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL21328362 | 0.91 | PDE4D (0.53) | PDE4DMTNR1BCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL11936777 | 0.87 | DRD2 (0.57) | PDE4DMTNR1BDRD2DRD1KCNH2 | |
| SCHEMBL21346707 | 0.83 | DRD2 (0.65) | CYP2D6DRD2DRD1DRD4KCNH2 | |
| SCHEMBL21346108 | 0.83 | DRD2 (0.65) | CYP2D6DRD2DRD1DRD4KCNH2 | |
| SCHEMBL12826271 | 0.82 | PDE4D (0.52) | PDE4DMTNR1BCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL12826406 | 0.80 | PDE4D (0.50) | PDE4DMTNR1BCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL23054182 | 0.79 | PDE4D (0.63) | PDE4DMTNR1BDRD2DRD1DRD4 | |
| SCHEMBL2742617 | 0.78 | PDE4D (0.54) | PDE4DDRD2DRD1DRD4 | |
| SCHEMBL10961753 | 0.78 | PDE4D (0.57) | PDE4DMTNR1BCYP2D6MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190275027-A1 | Bis-Benzyl-Tetrahydroisoquinoline Derivatives As Therapeutics For Filovirus | SOUTHWEST RESEARCH INSTITUTE | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190275027-A1 | Bis-Benzyl-Tetrahydroisoquinoline Derivatives As Therapeutics For Filovirus | TREH, TTN, TSN | PDE4D 1321/4885MTNR1B 1239/4885CYP3A4 2845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.